Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.100
-0.020 (-0.49%)
Jun 1, 2026, 3:10 PM EDT - Market open
Alterity Therapeutics Employees
Alterity Therapeutics had 9 employees as of June 30, 2025. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
$491,849
Profits / Employee
-$1,081,343
Market Cap
69.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 9 | -1 | -10.00% |
| Jun 30, 2024 | 10 | -1 | -9.09% |
| Jun 30, 2023 | 11 | -1 | -8.33% |
| Jun 30, 2022 | 12 | 1 | 9.09% |
| Jun 30, 2021 | 11 | -1 | -8.33% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| XBiotech | 87 |
| Acrivon Therapeutics | 76 |
| Seres Therapeutics | 66 |
| BeyondSpring | 44 |
| Cue Biopharma | 29 |
| Entera Bio | 22 |
| iBio, Inc. | 20 |
ATHE News
- 13 days ago - Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy - GlobeNewsWire
- 21 days ago - Alterity Therapeutics publishes quantitative susceptibility mapping MRI data - TheFly
- 21 days ago - Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy - GlobeNewsWire
- 25 days ago - Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 - GlobeNewsWire
- 4 weeks ago - Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update - GlobeNewsWire
- 4 weeks ago - Alterity Therapeutics Earnings release: Q3 2026 - Filings
- 4 weeks ago - Alterity Therapeutics Transcript: KOL event - Transcripts
- 5 weeks ago - Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting - TheFly